Abstract
To explain a bimodal pattern of hazard of relapse among early stage breast cancer patients identified in multiple databases, we proposed that late relapses result from steady stochastic progressions from single dormant malignant cells to avascular micrometastases and then on to growing deposits. However in order to explain early relapses, we had to postulate that something happens at about the time of surgery to provoke sudden exits from dormant phases to active growth and then to detection. Most relapses in breast cancer are in the early category. Recent data from Forget et al. suggest an unexpected mechanism. They retrospectively studied results from 327 consecutive breast cancer patients comparing various perioperative analgesics and anesthetics in one Belgian hospital and one surgeon. Patients were treated with mastectomy and conventional adjuvant therapy. Relapse hazard updated Sept 2011 are presented. A common Non-Steroidal Anti-Inflammatory Drug (NSAID) analgesic used in surgery produced far superior disease-free survival in the first 5 years after surgery. The expected prominent early relapse events in months 9-18 are reduced 5-fold. If this observation holds up to further scrutiny, it could mean that the simple use of this safe, inexpensive and effective anti-inflammatory agent at surgery might eliminate early relapses. Transient systemic inflammation accompanying surgery could facilitate angiogenesis of dormant micrometastases, proliferation of dormant single cells, and seeding of circulating cancer stem cells (perhaps in part released from bone marrow) resulting in early relapse and could have been effectively blocked by the perioperative anti-inflammatory agent.
Keywords: Breast cancer, early relapse, late relapse, angiogenesis, inflammation, surgery, analgesic, perioperative, metastases, bleeding, NSAID, dormancy.
Current Medicinal Chemistry
Title:Reduction of Breast Cancer Relapses with Perioperative Non-Steroidal Anti-Inflammatory Drugs: New Findings and a Review
Volume: 20 Issue: 33
Author(s): Michael Retsky, Romano Demicheli, William J.M. Hrushesky, Patrice Forget, Marc De Kock, Isaac Gukas, Rick A Rogers, Michael Baum, Vikas Sukhatme and Jayant S. Vaidya
Affiliation:
Keywords: Breast cancer, early relapse, late relapse, angiogenesis, inflammation, surgery, analgesic, perioperative, metastases, bleeding, NSAID, dormancy.
Abstract: To explain a bimodal pattern of hazard of relapse among early stage breast cancer patients identified in multiple databases, we proposed that late relapses result from steady stochastic progressions from single dormant malignant cells to avascular micrometastases and then on to growing deposits. However in order to explain early relapses, we had to postulate that something happens at about the time of surgery to provoke sudden exits from dormant phases to active growth and then to detection. Most relapses in breast cancer are in the early category. Recent data from Forget et al. suggest an unexpected mechanism. They retrospectively studied results from 327 consecutive breast cancer patients comparing various perioperative analgesics and anesthetics in one Belgian hospital and one surgeon. Patients were treated with mastectomy and conventional adjuvant therapy. Relapse hazard updated Sept 2011 are presented. A common Non-Steroidal Anti-Inflammatory Drug (NSAID) analgesic used in surgery produced far superior disease-free survival in the first 5 years after surgery. The expected prominent early relapse events in months 9-18 are reduced 5-fold. If this observation holds up to further scrutiny, it could mean that the simple use of this safe, inexpensive and effective anti-inflammatory agent at surgery might eliminate early relapses. Transient systemic inflammation accompanying surgery could facilitate angiogenesis of dormant micrometastases, proliferation of dormant single cells, and seeding of circulating cancer stem cells (perhaps in part released from bone marrow) resulting in early relapse and could have been effectively blocked by the perioperative anti-inflammatory agent.
Export Options
About this article
Cite this article as:
Retsky Michael, Demicheli Romano, Hrushesky J.M. William, Forget Patrice, Kock De Marc, Gukas Isaac, Rogers A Rick, Baum Michael, Sukhatme Vikas and Vaidya S. Jayant, Reduction of Breast Cancer Relapses with Perioperative Non-Steroidal Anti-Inflammatory Drugs: New Findings and a Review, Current Medicinal Chemistry 2013; 20 (33) . https://dx.doi.org/10.2174/09298673113209990250
DOI https://dx.doi.org/10.2174/09298673113209990250 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metal-dithiocarbamate complexes: chemistry and biological activity
Mini-Reviews in Medicinal Chemistry Histone Modifications as Molecular Targets in Nasopharyngeal Cancer
Current Medicinal Chemistry Glioblastoma Multiforme and its Cell Interruption
Current Cancer Therapy Reviews Photoacoustic Detection and Imaging of Cancer Using Nanoparticles as Optical Contrast Agents
Recent Patents on Nanomedicine The Role of CXCR3 in Neurological Diseases
Current Neuropharmacology Paving Roads for New Drugs in Oncology
Recent Patents on Anti-Cancer Drug Discovery Chemotherapeutic Properties of n-3 Polyunsaturated Fatty Acids - Old Concepts and New Insights
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Synthesis, Radiosynthesis and Metabolism of 131I-Y-c(CGRRAGGSC)
Anti-Cancer Agents in Medicinal Chemistry The Potential of PI3K/AKT/mTOR Signaling as a Druggable Target for Endometrial and Ovarian Carcinomas
Current Drug Targets Clomiphene Citrate, Metformin or Both for Ovulation Induction in Therapy Naïve Women with Polycystic Ovary Syndrome (PCOS)? A Descriptive Review
Current Drug Therapy Development of Folate-Conjugated PEGylated Poly (d,l-lactide-co-glycolide) Nanoparticulate Carrier for Docetaxel
Current Nanoscience The Use of Metabolising Systems for In Vitro Testing of Endocrine Disruptors
Current Drug Metabolism Novel Non-Steroidal Anti-Inflammatory Drugs: What we have Learned from Animal Studies
Current Drug Targets - Inflammation & Allergy Immunocal® and Preservation of Glutathione as a Novel Neuroprotective Strategy for Degenerative Disorders of the Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) From Blood-to-Brain: Regulating the Permeability of the Blood-Brain Barrier
Current Psychopharmacology Diverse Thiophenes as Scaffolds in Anti-cancer Drug Development: A Concise Review
Mini-Reviews in Medicinal Chemistry Specific Targeted Therapy: A New Tool for the Destruction of Cancer
Current Drug Therapy Curcumin has Bright Prospects for the Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Design Trichinella spiralis and Tumors: Cause, Coincidence or Treatment?
Anti-Cancer Agents in Medicinal Chemistry Hypersensitivity to Antineoplastic Agents
Current Pharmaceutical Design